Holen Sie sich die Stockscreener-App
83.41
0.20%
-0.17
Vorhandelsmarkt:
83.41
Schlusskurs vom Vortag:
$83.58
Offen:
$83.54
24-Stunden-Volumen:
1.34M
Relative Volume:
1.18
Marktkapitalisierung:
$7.24B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-35.38
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
+9.12%
1M Leistung:
+11.33%
6M Leistung:
+152.99%
1J Leistung:
+385.51%
1-Tages-Spanne:
$81.70
$84.92
1-Wochen-Bereich:
$74.79
$84.92
52-Wochen-Spanne:
$13.93
$84.92
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
83.41 | 7.26B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103 - Moomoo
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $112 - Moomoo
Spyre Therapeutics (SYRE) Reveals Promising Results from SKYLINE Trial - GuruFocus
Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80 on Positive SPY002 Results, Maintains Outperform Rating - marketscreener.com
Spyre reports positive phase 2 trial results for UC drug By Investing.com - Investing.com South Africa
Spyre reports positive phase 2 trial results for UC drug - Investing.com UK
Spyre says bowel disease drug cuts inflammation in mid-stage trial - Reuters
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - The Manila Times
Spyre Therapeutics posts positive Phase 2 SKYLINE Part A results for SPY002, RHI -10.7 (p - TradingView
Spyre Therapeutics (NASDAQ: SYRE) posts positive Phase 2 SPY002 ulcerative colitis data - Stock Titan
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Certain Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
SYRE completes enrollment in SKYWAY basket study on SPY072, stock up - MSN
Spyre Therapeutics stock hits 52-week high at 79.75 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 79.75 USD - Investing.com
Capital International Investors Purchases 1,100,000 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Spyre Therapeutics grants inducement awards to four employees - scanx.trade
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Grants Stock Options to Non-Executive Employees as Part of Equity Inducement Awards - Quiver Quantitative
Arrowpoint Investment Partners Singapore Pte. Ltd. Buys New Shares in Spyre Therapeutics, Inc. $SYRE - MarketBeat
SYRE Maintains Buy Rating by Deutsche Bank -- Price Target Raised to $115 - GuruFocus
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up - sharewise.com
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $115 From $102, Maintains Buy Rating - marketscreener.com
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Deutsche Bank raises Spyre stock price target on competitor setback By Investing.com - Investing.com South Africa
Deutsche Bank raises Spyre stock price target on competitor setback - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock By Investing.com - Investing.com South Africa
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock - Investing.com UK
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock - Investing.com
Spyre Therapeutics (SYRE) CEO Turtle sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options - Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sloan Sheldon | Chief Medical Officer |
Jun 03 '26 |
Sale |
75.00 |
8,333 |
624,975 |
0 |
| Turtle Cameron | Chief Executive Officer |
Jun 01 '26 |
Sale |
70.43 |
15,000 |
1,056,486 |
597,540 |
| Burrows Scott L | Chief Financial Officer |
Jun 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
105,494 |
| Burrows Scott L | Chief Financial Officer |
Jun 01 '26 |
Sale |
71.06 |
7,500 |
532,937 |
97,994 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):